NCT06502743View on ClinicalTrials.gov

First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Endometrial CancerRecurrent Endometrial CarcinomaEndometrial CarcinomaGynecologycal CancerEndometrial Neoplasms
Interventions
DRUG

Nesuparib

Nesuparib 150mg or 100mg, QD, PO

DRUG

Pembrolizumab

Pembrolizumab 400mg, IV, Q6W

Trial Locations (6)

Unknown

RECRUITING

National Cancer Center, Kyeonggi-do

RECRUITING

Korea University Guro Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul Asan Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance hospital, Seoul

Sponsors

Collaborators (1)

Onconic Therapeutics Inc.
All Listed Sponsors
collaborator

Onconic Therapeutics Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yonsei University

OTHER

NCT06502743 - First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer | Biotech Hunter | Biotech Hunter